Sees FY25 adjusted EBITDA $150M-$200M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Mpox strain with higher transmission rate detected in Congo, Bloomberg reports
- Is EBS a Buy, Before Earnings?
- Emergent BioSolutions, Smith raise awareness on opioid poisonings
- Emergent BioSolutions starts enrollment in Africa or cDC-led MPox study
- Emergent BioSolutions Outlines Growth at J.P. Morgan Conference